<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; US-FDA</title>
	<atom:link href="http://www.tapanray.in/tag/us-fda/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In a Quandary of Drug Quality, Price Control, Innovation and Patient Interest in India</title>
		<link>http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india</link>
		<comments>http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/#comments</comments>
		<pubDate>Mon, 06 Mar 2017 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[denial]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Quandary]]></category>
		<category><![CDATA[Que Sera]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Sera]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US-FDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8120</guid>
		<description><![CDATA[The patients in India have every reason to apprehend, whether the prescription drugs that they consume are efficacious, safe and conform to the government approved prices, alongside another important question: Do they affordable access to the fruits of innovation? The &#8230; <a href="http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Takeover Magician To Tango Again On A Bold New ‘Sunny’ Tune</title>
		<link>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune</link>
		<comments>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/#comments</comments>
		<pubDate>Mon, 14 Apr 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Dilip]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[magician]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Shanghvi]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[sunny]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[takeover]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wand]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5240</guid>
		<description><![CDATA[The consolidation process of the Indian pharmaceutical industry continues in its own pace. Most recently, the homegrown pharma takeover magician is all set to tango yet again with a bold ‘Sunny’ tune. The low profile creator of high value ‘Sun &#8230; <a href="http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Just Born A Pharma Goliath: Would India Be Impacted?</title>
		<link>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=just-born-a-pharma-goliath-would-india-be-impacted</link>
		<comments>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/#comments</comments>
		<pubDate>Mon, 03 Mar 2014 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actavis]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chilcott]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Goliath]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[MerckSerono]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seksharia]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[super]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[Watson]]></category>
		<category><![CDATA[Zentiva]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5030</guid>
		<description><![CDATA[Just born a potential pharma Goliath, as Actavis &#8211; the Dublin-based one of the largest global generic drug makers, in its biggest ever purchase, acquires New York based R&#38;D based pharma major &#8211; Forest Laboratories, for a whopping US$ 25 billion. &#8230; <a href="http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
